Core Viewpoint - China Construction Bank Corporation has obtained a patent for a "transaction processing method and device, computer equipment, and computer-readable storage medium," with the authorization announcement number CN113077256B, applied for on March 2021 [1]. Group 1: Company Overview - China Construction Bank Corporation was established in 2004 and is located in Beijing, primarily engaged in monetary financial services [1]. - The registered capital of China Construction Bank Corporation is approximately 26.16 billion RMB [1]. Group 2: Investment and Intellectual Property - The company has invested in 37 enterprises and participated in 44,981 bidding projects [1]. - In terms of intellectual property, China Construction Bank Corporation holds 1,895 trademark records and 5,000 patent records, along with 149 administrative licenses [1].

格隆汇3月17日丨世运电路(603920.SH)在互动平台表示，公司通过OEM模式切入英伟达服务器供应链体 系后，依托在高多层板、高频高速PCB领域的核心工艺优势及稳定的量产交付能力，现阶段对英伟达服 务器相关PCB产品的供货量实现快速增长。AI服务器在公司营业收入属于成长型业务板块，目前在公司 营业收入的占比仍较少。未来业务增长依赖AI服务器需求放量，存在市场竞争加剧、产品价格波动、 技术更新迭代不及预期等风险，公司提请投资者注意风险，理性看待。 ...

招商证券主要观点如下： 白羽鸡：节后毛鸡价格回落，鸡产品价格显著好于往年 2月主产区毛鸡均价7.49元/千克，同比+24%，环比-1.9%；鸡苗均价2.52元/羽，同比+19.2%，环比 +4.4%；鸡产品均价9300元/吨，同比+2.8%，环比+0.5%；毛鸡养殖端羽均亏损0.02元。本月鸡源相较充 足，但节后需求端承接有限，鸡价自春节后逐步小幅回落；而由于前期鸡苗成本处于低位水平，养殖端 仍有一定盈利；鸡产品价格显著好于往年。节后鸡苗供应量不大，种禽企业挺价意愿明显，支撑苗价向 好。 智通财经APP获悉，招商证券发布研报称，2月鸡源相较充足，但节后需求端承接有限，鸡价自春节后 逐步小幅回落；而由于前期鸡苗成本处于低位水平，养殖端仍有一定盈利；鸡产品价格显著好于往年。 节后鸡苗供应量不大，种禽企业挺价意愿明显，支撑苗价向好。春节期间黄羽鸡餐饮消费及家庭消费改 善，尤其节前慢速鸡价更为坚挺，而节假日期间快速鸡也保持着较好盈利。当前黄羽肉鸡出栏成本已回 落至低位，2月份头部养殖企业羽均盈利或已提升至2元左右，同时看好26年黄鸡高景气延续。 结合产能来看，当前父母代产能已降至历史偏低位水平，再加之2025年行业亏 ...

Core Viewpoint - China Construction Bank has obtained a patent for a mobile payment method and device based on electronic certificates, indicating its commitment to innovation in financial technology [1]. Company Overview - China Construction Bank Corporation was established in 2004 and is located in Beijing, primarily engaged in monetary financial services [1]. - The registered capital of China Construction Bank is approximately 26.16 billion RMB [1]. Investment and Business Activities - The company has invested in 37 enterprises and participated in 44,982 bidding projects [1]. - China Construction Bank holds 1,895 trademark registrations and 5,000 patent records, showcasing its extensive intellectual property portfolio [1]. - The bank has obtained 149 administrative licenses, reflecting its compliance and operational capabilities [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感 染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。 格隆汇3月17日丨上海医药(601607.SH)公布，公司下属上海上药新亚药业有限公司（称"上药新亚"）的 注射用头孢唑林钠（称"该药品"）收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知 书编号：2026B01286、2026B01287），该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Core Viewpoint - China CRRC's stock price decreased by 0.47% on March 17, with a trading volume of 824 million yuan and a market capitalization of 183.099 billion yuan [1][11]. Group 1: Company Overview - China CRRC Corporation Limited is located in Haidian District, Beijing, established on December 28, 2007, and listed on August 18, 2008. The company primarily engages in the research, manufacturing, sales, repair, and leasing of railway locomotives, passenger cars, EMUs, urban rail vehicles, and key components [8]. - The revenue composition of China CRRC includes: railway equipment 49.86%, new industries 34.01%, urban rail and infrastructure 14.53%, and modern services 1.60% [8]. - As of September 30, 2025, the number of shareholders is 498,200, a decrease of 2.91% from the previous period, with an average of 49,029 circulating shares per shareholder, an increase of 3.01% [8]. Group 2: Financial Performance - For the period from January to September 2025, China CRRC achieved a revenue of 183.865 billion yuan, representing a year-on-year growth of 20.50%. The net profit attributable to shareholders was 9.964 billion yuan, with a year-on-year increase of 37.53% [8]. - China CRRC has distributed a total of 63.599 billion yuan in dividends since its A-share listing, with 20.663 billion yuan distributed over the past three years [9]. Group 3: Shareholding and Institutional Holdings - Among the top ten circulating shareholders, China Securities Finance Corporation holds 606 million shares, remaining unchanged from the previous period, while Hong Kong Central Clearing Limited holds 442 million shares, a decrease of 400 million shares from the previous period [19]. - The company is classified as a "state-owned enterprise" with its actual controller being the State-owned Assets Supervision and Administration Commission or central state-owned enterprises [3][12]. Group 4: Market Activity and Technical Analysis - The main capital flow showed a net outflow of 37.741 million yuan today, accounting for 0.05%, with the industry ranking at 30 out of 33, indicating a continuous reduction in main capital over three days [4][14]. - The average trading cost of the stock is 6.93 yuan, with the current stock price fluctuating between resistance at 6.47 yuan and support at 6.25 yuan, suggesting potential for range trading [7][17].

3月17日，赣锋锂业跌2.99%，成交额21.49亿元，换手率2.55%，总市值1436.03亿元。 异动分析 盐湖提锂+金属钴+小金属概念+锂电池概念+特斯拉概念 1、公司持有的阿根廷Cauchari-Olaroz项目的含锂卤水资源量为约合2,458万吨LCE，是目前全球最大的 盐湖提锂项目之一，支持年产量超过4万吨电池级碳酸锂并持续40年。 2、2020年6月29日公告显示：公司以自有资金 30,011.7 万元人民币在江西省产权交易所成功竞得新余高 新投资有限公司持有的赣州腾远钴业新材料股份有限公司6,514,553 股份，本次交易完成后，公司将持 有腾远钴业 6.8966%的股权。 3、2020年6月29日公告显示：公司以自有资金 30,011.7 万元人民币在江西省产权交易所成功竞得新余高 新投资有限公司持有的赣州腾远钴业新材料股份有限公司6,514,553 股份，本次交易完成后，公司将持 有腾远钴业 6.8966%的股权。 4、江西赣锋锂业集团股份有限公司的主营业务是从磷酸铁锂蓄电池废物（我们最具代表性的回收产品 之一）回收硫酸锂溶液的回收流程公司的主要产品是氢氧化锂、碳酸锂、金属锂、固体电解质材 ...

3月17日，招商证券涨1.01%，成交额9.70亿元，换手率0.81%，总市值1395.79亿元。 异动分析 证金持股+国企改革+央企国企改革 1、公司前十大流通股东中包含中央汇金资产管理有限责任公司或中国证券金融股份有限公司。 2、公司属于国有企业。公司的最终控制人为国务院国有资产监督管理委员会。 3、公司最终控制人为国务院国有资产监督管理委员会 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入3515.93万，占比0.04%，行业排名19/50，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入29.75亿，当前无连续增减仓现象，主力趋势不明显。 | 区间 | 今日 | 近3日 | 近5日 | 近10日 | 近20日 | | --- | --- | --- | --- | --- | --- | | 主力净流入 | 3398.77万 | 2246.84万 | -76.27万 | -1.18亿 | -7.48亿 | 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.18亿，占总成交额的1.08%。 技术面：筹码平均交易成本为17.0 ...